Clinical trial · Interventional
Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer
An Open-label, Multi-Centre Trial, Bridging Efficacy and Safety of Degarelix One-Month Dosing Regimen in Korean Patients With Prostate Cancer Requiring Androgen Ablation Therapy
NCT01071915CI-TRIAL-00009428completedPhase 3Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an open-label, multi-centre single arm trial to investigate efficacy and safety of degarelix in Korean patients with prostate cancer for bridging between CS21 trial (NCT00295750) results.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Degarelix 240/80 mg | Drug | Degarelix | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Degarelix 240/80 mg
- description
- The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenace of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day intervals from day 28 to day 168.
- interventionNames
- Drug: Degarelix 240/80 mg
Primary outcomes (1)
- measure
- Cumulative Probability of Testosterone at Castrate Level (≤0.5 ng/mL) From Day 28 to Day 196
- timeFrame
- Day 28 to Day 196
Secondary outcomes (6)
- measure
- Proportion of Patients With Testosterone Level ≤0.5 ng/mL at Day 3
- timeFrame
- At day 3
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Has given written informed consent before any trial-related activity is performed. * Has a histologically confirmed (Gleason graded) adenocarcinoma of the prostate (all stages) (except for neoadjuvant hormonal therapy/ includes patients with rising PSA after prostatectomy or radiotherapy) * Is a male patient aged 18 years or older * Has a screening serum testosterone level \>1.5 ng/mL * Has an ECOG (Eastern Cooperative Oncology Group) score of ≤ 2 * Has a screening PSA value of ≥2 ng/mL * Has a life expectancy of at least 12 months Exclusion Criteria: * Has had previous or is currently under hormonal management of prostate cancer. However, prostatectomy or radiotherapy with curative intention, neoadjuvant/adjuvant hormonal therapy are accepted for a maximum duration of 6 months, at least 6 months prior to Screening Visit * Is currently treated with a 5-α-reductase inhibitor * Is considered to be candidate for curative therapy, i.e. radical prostatectomy or radiotherapy * Has a history of severe untreated asthma, anaphylactic reactions or severe urticaria and/or angioedema * Has hypersensitivity towards any component of the investigational medicinal product * A marked baseline prolongation of QT/QTcF interval * A history of additional risk factors for Torsade de Pointes ventricular arrhythmias * Has had cancer within the last five years except prostate cancer and surgically removed basal or squamous cell carcinoma of the skin * Has a known or suspect hepatic, symptomatic biliary disease * Has elevated serum ALT level more than the upper limit of normal or serum total bilirubin level above the upper level of normal range at the Screening Visit and confirmed with a second measurement within 21 days * Has other clinically significant laboratory abnormalities * Has a clinically significant disorder (other than prostate cancer) or any other condition, including alcohol or drug abuse * Has a mental incapacity or language barriers precluding adequate understanding or co- operation * Has received an investigational drug within the last 28 days preceding Screening Visit or longer if considered to possibly influence the outcome of the current trial * Has previously participated in any degarelix trial
References
Publications (0)
Data not yet available
No reference posted for this study.